Skip to Main Content

Paper Details

DESTINY-Breast03 trial: some questions remain - Authors' reply.
Lancet
1
2023
Author NameAffiliation
Giuseppe CuriglianoEuropean Institute of Oncology, IRCCS, University of Milano
  • 1 - 1

Datasets

Release 1.2